Episode 23. Bispecific Antibodies in Myeloma

In this episode, we delve into the latest data on bispecific antibodies in multiple myeloma with Dr. Ajai Chari. Here are the key studies discussed:

1. Teclistamab (MajesTEC-1 trial): https://pubmed.ncbi.nlm.nih.gov/35661166/

2. Correlative analysis from MajesTEC-1 trial: https://ashpublications.org/blood/article/140/Supplement%201/241/487619

3.  Talquetamab (MonumenTAL-1 trial): https://pubmed.ncbi.nlm.nih.gov/36507686/

4. Phase 1 trial of fixed-duration cevostamab: 

https://ashpublications.org/blood/article/140/Supplement%201/4415/492339

5. Phase 1 trial of ABBV-383: https://pubmed.ncbi.nlm.nih.gov/36029527/

6. Paper summarizing infections with different bispecific antibodies in myeloma: https://pubmed.ncbi.nlm.nih.gov/36716411/